Synova’s Post

Novonesis - A new beginning..... Great vision for the future combination between Novozymes and Chr. Hansen Learn more in the video below or in the press release here:  https://lnkd.in/dTxqDB-p Until final merger control approvals are received, and the proposed combination completes, Novozymes and Chr. Hansen operate as completely separate companies. #biosolutions #novonesis #novozymes #chrhansen

Synergy realization in #pe #deals is extremely challenging. Virtas Partners has built out a solution to "size the prize" during due diligence on #synergy opportunities and go capture the synergies post close. See a recent case study here. 👉 https://bit.ly/3UFXUqt #CaseStudy #VirtasPartners #SynergyOpportunities #duediligence #integrations #deals

So, IPH have just announced that they have acquired a third and presumably final Canadian patent firm - ROBIC: https://lnkd.in/dCJqX35n Where next? Presumably, South America and then the Middle East. Will this acquisition act as a catalyst to reverse IPH's share price which for the last year has been on a slow downward trajectory? If you're a principal of one of the member firms with shares/share options you must be hoping so. What is clear is that IPH have a clear strategic plan, a highly competent CEO and the benefit of first mover advantage. #patents #iph #australia #patentfirms #asx

⚖️Ilumina/Grail sheds light into the use (or abuse) of art.22 of the EUMR. ❓The one-million dollar question that we all have in mind today: Will the Commission and National Competition authorities revamp their merger thresholds to be able to review innovation-driven mergers? https://lnkd.in/eYg9dBP7 #competitionlaw #innovation #mergercontrol

SES to Acquire Intelsat in Compelling Transaction Focused on the Future April 30, 2024 - https://lnkd.in/eTzKCHNM SES S.A. (“SES”) and Intelsat S.A. (“Intelsat”) announce an agreement for SES to acquire Intelsat through the purchase of 100% of the equity of Intelsat Holdings S.a.r.l. for a cash consideration of $3.1 billion (€2.8 billion) and certain contingent value rights. The combination will create a stronger multi-orbit operator with greater coverage, improved resiliency, expanded suite of solutions, enhanced resources to profitably invest in innovation, and benefit from the collective talent, expertise, and track record of both companies.

How can strategic guidance and unconflicted advice transform a business? MedQIA, LLC turned to GHJ amidst two prospective offers in the evolving healthcare tech industry. Our Growth Planning and Strategic Advisory Practice evaluated the offers, advised on investment banking selection and supported MedQIA throughout a complex merger process. The result? A successful merger with WorldCare Clinical to create Voiant, a leading AI-based clinical trial imaging platform. Discover how GHJ’s expertise can position your business for long-term success. https://bit.ly/4dq5T2G #YourHomeTeamAdvantage

Yearly med-tech deal value soars 33%, M&As decline by 64% Echoing trends seen in 2022, the med-tech industry concluded 2023 with a continued surge in deal value juxtaposed against a more substantial decline in M&A value. Deal value for the year, including licensings, collaborations and joint ventures, reached $10.63 billion from 1,656 deals, the highest annual value in BioWorld’s records. It is a 33% increase in value over 2022, despite a 16% reduction in the number of deals. Last year saw a higher number of deals at 1,961, but a lower value at $7.99 billion. The 2023 value also surpassed 2021’s $2.23 billion (from 1,651 deals) and 2020’s $4.44 billion (from 1,400 deals).

Mark your calendar! I’ll be speaking at DGE’s 5th Clinical Trial Agreements on August 22nd at 11:45. Learn about the critical role of CTAs in M&As, AI advancements, M&A due diligence, and the power of standard templates. Click below to register now. #clinicaltrialcompliance #MandA #klf

Join me at Dynamic Global Events (DGE)'s 5th Clinical Trial Agreements on August 22nd at 11:45! We'll delve into the pivotal role CTAs play in mergers and acquisitions, especially in pharma and biotech. Learn about key M&A due diligence, the transformative potential of AI in CTAs, and the importance of standard templates for streamlining clinical trials. Click below to register now. #clinicaltrials #clinicaltrialagreements #mergersandacquisitions #DGEvents

Join me at Dynamic Global Events (DGE)'s 5th Clinical Trial Agreements on August 22nd at 11:45! We'll delve into the pivotal role CTAs play in mergers and acquisitions, especially in pharma and biotech. Learn about key M&A due diligence, the transformative potential of AI in CTAs, and the importance of standard templates for streamlining clinical trials. Register now. Link in comments. #clinicaltrials #clinicaltrialagreements #mergersandacquisitions #DGEvents